AIDS
MCID: HMN044
MIFTS: 74

Human Immunodeficiency Virus Type 1 (AIDS)

Categories: Genetic diseases, Immune diseases

Aliases & Classifications for Human Immunodeficiency Virus Type 1

MalaCards integrated aliases for Human Immunodeficiency Virus Type 1:

Name: Human Immunodeficiency Virus Type 1 57
Hiv/aids 57 38 43 3
Aids 57 76 55 3
Human Immunodeficiency Virus Type 1, Susceptibility to 57 29 6
Aids, Delayed/rapid Progression to 57 13
Hiv-1 Viremia, Susceptibility to 57 6
Hiv1 Infection 57 38
Hiv-1 57 38
Rapid Progression to Aids from Hiv1 Infection 57
Human Immunodeficiency Virus I Infection 73
Acquired Immunodeficiency Syndrome 73
Hiv1 Infection, Resistance to 57
Hiv Type 1, Susceptibility to 57
Hiv Infection, Resistance to 57
Hiv/aids, Susceptibility to 57
Aids, Rapid Progression to 57
Aids, Slow Progression to 57
Hiv-1, Susceptibility to 57
Hiv-1, Resistance to 57
Aids, Resistance to 57
Hiv1, Resistance to 57
Hiv-Infection/aids 73
Hiv-1 Viremia 57
Hiv Type 1 57
Hiv1 57

Classifications:



External Ids:

OMIM 57 609423

Summaries for Human Immunodeficiency Virus Type 1

MedlinePlus : 43 HIV stands for human immunodeficiency virus. It harms your immune system by destroying the white blood cells that fight infection. This puts you at risk for serious infections and certain cancers. AIDS stands for acquired immunodeficiency syndrome. It is the final stage of infection with HIV. Not everyone with HIV develops AIDS. HIV most often spreads through unprotected sex with an infected person. It may also spread by sharing drug needles or through contact with the blood of an infected person. Women can give it to their babies during pregnancy or childbirth. The first signs of HIV infection may be swollen glands and flu-like symptoms. These may come and go within two to four weeks. Severe symptoms may not appear until months or years later. A blood test can tell if you have HIV infection. Your health care provider can do the test, or you can use a home testing kit. Or to find free testing sites, call the national referral hotline at 1-800-CDC-INFO (1-800-232-4636 in English and en español; 1-888-232-6348 - TTY). There is no cure, but there are many medicines that fight HIV infection and lower the risk of infecting others. People who get early treatment can live with the disease for a long time. Strategies to reduce the risk of HIV infection include not having sex, limiting your number of sexual partners, never sharing needles, and using condoms the right way every time you have sex. People who are at high risk may take HIV prevention medicines.

MalaCards based summary : Human Immunodeficiency Virus Type 1, also known as hiv/aids, is related to aspergillosis and immunodysregulation, polyendocrinopathy, and enteropathy, x-linked, and has symptoms including fever and pruritus. An important gene associated with Human Immunodeficiency Virus Type 1 is CXCL12 (C-X-C Motif Chemokine Ligand 12), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Dolutegravir and Maraviroc have been mentioned in the context of this disorder. Affiliated tissues include testes, t cells and brain, and related phenotypes are hematopoietic system and immune system

OMIM : 57 The pathogenesis of HIV infection and the progression from infection to AIDS vary significantly between exposed individuals. Infection occurs after the virus, which has macrophage (M)- and T lymphocyte (T)-tropic strains and more than 12 subtypes, survives an array of nonspecific, nongenetic environmental and host factors. (609423)

CDC : 3 Help

Wikipedia : 76 Human immunodeficiency virus infection and acquired immune deficiency syndrome (HIV/AIDS) is a spectrum... more...

Related Diseases for Human Immunodeficiency Virus Type 1

Diseases related to Human Immunodeficiency Virus Type 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1772)
# Related Disease Score Top Affiliating Genes
1 aspergillosis 32.3 CD209 IFNG IL10
2 immunodysregulation, polyendocrinopathy, and enteropathy, x-linked 31.5 CCNT1 CCR5 CD209 CD9 CXCL12 IFNG
3 viral infectious disease 31.3 CCL3 CCR5 CD209 IFNG IL10 ITIH4
4 acquired immunodeficiency syndrome 31.3 CCL3 CCR2 CCR5 IFNG IL10 ITIH4
5 encephalitis 31.1 CCL2 CCR5 CD209 ITIH4 TLR3
6 pneumonia 30.9 CCL11 CCL2 CCL3 IL10
7 human immunodeficiency virus infectious disease 30.8 CCL3 CCR2 CCR5 CXCL12 IFNG IL10
8 meningitis 30.8 CCL2 CCL3 IFNG IL10
9 pulmonary tuberculosis 30.8 CCL3 IFNG IL10
10 measles 30.6 CD209 IFNG TLR3
11 cytomegalovirus retinitis 30.6 CCR2 CCR5 CD9 IFNG
12 uveitis 30.5 CCL2 IFNG IL10
13 malaria 30.5 CCL11 CCL2 CCL3 IFNG IL10
14 leishmaniasis 30.5 CCL2 CCR5 IFNG IL10
15 schistosomiasis 30.5 CCL3 IFNG IL10
16 lymphadenitis 30.5 CD209 IFNG IL10
17 west nile virus 30.5 CCR5 CD209 TLR3
18 severe acute respiratory syndrome 30.4 CCL2 CD209 IFNG
19 sporotrichosis 30.4 IFNG IL10
20 multiple sclerosis 30.2 CCL2 CCL3 CCR5 IFNG IL10
21 bacterial infectious disease 30.2 CCL2 IFNG IL10 TLR3
22 mucocutaneous leishmaniasis 30.1 CCR5 IL10 TLR3
23 periodontitis 30.1 CCL2 IFNG IL10
24 asthma 30.1 CCL11 CCL2 CCL3 CXCL12 IFNG IL10
25 mycobacterium tuberculosis 1 30.1 CD209 IFNG IL10
26 bronchiolitis 30.0 CCL11 CCL3 IFNG IL10 IL4R
27 leprosy 3 30.0 CD209 IFNG IL10
28 chagas disease 30.0 CCL2 CCL3 CCR5 IFNG IL10
29 variola major 30.0 CCL3 IFNG TLR3
30 trypanosomiasis 30.0 CCL2 CCL3 IFNG IL10
31 rheumatoid arthritis 30.0 CCL2 CCL3 CCR2 CXCL12 IFNG IL10
32 extrapulmonary tuberculosis 30.0 CCL2 IFNG IL10
33 interstitial lung disease 30.0 CCL2 IFNG IL10
34 retinal vasculitis 30.0 CCL2 CX3CR1 TLR3
35 toxoplasmosis 29.9 CCR5 IFNG IL10
36 hematopoietic stem cell transplantation 29.9 HLA-C IFNG IL10 KIR3DL1
37 pyelonephritis 29.9 CCL2 CXCR1 IL10
38 graft-versus-host disease 29.9 HLA-C IFNG IL10
39 inflammatory bowel disease 29.9 CCL11 CCL2 CCR5 IFNG IL10 IL4R
40 skin disease 29.8 CCL11 HLA-C IFNG IL10
41 scabies 29.8 CCL11 IL10
42 dermatitis, atopic 29.8 CCL11 CCL2 IFNG IL10 IL4R
43 macular degeneration, age-related, 1 29.8 CCL2 CCR2 CX3CR1 TLR3
44 penicillin allergy 29.6 IFNG IL10 IL4R
45 hemorrhagic fever 29.6 CD209 IFNG IL10
46 hand, foot and mouth disease 29.6 IFNG IL10 TLR3
47 mouth disease 29.6 IFNG IL10 TLR3
48 fungal meningitis 29.6 CCL2 IFNG IL10
49 behcet syndrome 29.6 CCL3 CCR5 HLA-C IFNG IL10 KIR3DL1
50 spondyloarthropathy 29.6 HLA-C IFNG IL10

Graphical network of the top 20 diseases related to Human Immunodeficiency Virus Type 1:



Diseases related to Human Immunodeficiency Virus Type 1

Symptoms & Phenotypes for Human Immunodeficiency Virus Type 1

Clinical features from OMIM:

609423

UMLS symptoms related to Human Immunodeficiency Virus Type 1:


fever, pruritus

MGI Mouse Phenotypes related to Human Immunodeficiency Virus Type 1:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.1 CCL11 CCR2 CCR5 CD9 CX3CR1 CXCL12
2 immune system MP:0005387 10.07 CCL11 CCL2 CCR2 CCR5 CD9 CX3CR1
3 liver/biliary system MP:0005370 9.7 CCR2 CCR5 CXCL12 IFNG IL10 IL4R
4 neoplasm MP:0002006 9.43 CCR2 CCR5 IFNG IL10 ITIH4 TLR3
5 respiratory system MP:0005388 9.17 CCL11 CCR2 CD9 IFNG IL10 IL4R

Drugs & Therapeutics for Human Immunodeficiency Virus Type 1

Drugs for Human Immunodeficiency Virus Type 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 617)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Dolutegravir Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1051375-16-6 54726191
2
Maraviroc Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 376348-65-1 3002977
3
Ritonavir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 155213-67-5 392622
4
Darunavir Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 206361-99-1, 635728-49-3 213039
5
Mycophenolic acid Approved Phase 4,Phase 3,Not Applicable 24280-93-1 446541
6
Zidovudine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 30516-87-1 35370
7
Emtricitabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 143491-57-0 60877
8
Efavirenz Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 154598-52-4 64139
9
Lamivudine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 134678-17-4 60825
10
Lopinavir Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 192725-17-0 92727
11
Alendronate Approved Phase 4,Phase 3,Phase 2 66376-36-1, 121268-17-5 2088
12
Calcium Carbonate Approved, Investigational Phase 4,Phase 2 471-34-1
13
Rilpivirine Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 500287-72-9
14
Cobicistat Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1004316-88-4
15
Nelfinavir Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 159989-64-7 64143
16
Stavudine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 3056-17-5 18283
17
Didanosine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 69655-05-6 50599
18
Abacavir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 136470-78-5 65140 441300
19
Amprenavir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 161814-49-9 65016
20
Rifabutin Approved, Investigational Phase 4,Phase 2,Phase 1 72559-06-9 6323490
21
Nevirapine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 129618-40-2 4463
22
Pentoxifylline Approved, Investigational Phase 4 6493-05-6 4740
23
Ribavirin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 36791-04-5 37542
24
Methadone Approved Phase 4,Phase 1,Not Applicable 76-99-3 4095
25
Guaifenesin Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Not Applicable 93-14-1 3516
26
Enfuvirtide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 159519-65-0 16130199
27
Peginterferon alfa-2a Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 198153-51-4 5360545
28
Fosamprenavir Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 226700-79-4 131536
29
Indinavir Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 150378-17-9 5362440
30
Rifampicin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 13292-46-1 5458213 5381226
31
Peginterferon alfa-2b Approved Phase 4,Phase 3,Phase 2,Phase 1 99210-65-8, 215647-85-1
32
Naloxone Approved, Vet_approved Phase 4,Phase 3,Phase 1,Not Applicable 465-65-6 5284596
33
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 52485-79-7 40400 644073
34
Trimethoprim Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 738-70-5 5578
35
Sulfamethoxazole Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 723-46-6 5329
36
Acyclovir Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 59277-89-3 2022
37
Etravirine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 269055-15-4 193962
38
Atovaquone Approved Phase 4 95233-18-4 74989
39
Proguanil Approved Phase 4 500-92-5 4923
40
Saquinavir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 127779-20-8 60787
41
Everolimus Approved Phase 4,Phase 1,Phase 2 159351-69-6 6442177
42
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 22916-47-8 4189
43
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 53123-88-9 46835353 6436030 5284616
44 tannic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
45
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 94-09-7, 1994-09-7 2337
46
Angiotensin II Approved, Investigational Phase 4,Phase 2,Phase 1 11128-99-7, 68521-88-0, 4474-91-3 172198 65143
47
Losartan Approved Phase 4,Phase 2 114798-26-4 3961
48
Tipranavir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 174484-41-4 65027
49
Isoniazid Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 54-85-3 3767
50
Ethambutol Approved Phase 4,Phase 3,Phase 2 74-55-5 3279 14052

Interventional clinical trials:

(show top 50) (show all 2233)
# Name Status NCT ID Phase Drugs
1 A Comparison of Virco®TYPE HIV-1 Testing Versus Expert Interpretation of Genotypic Results for Control of HIV-1 Replication Unknown status NCT00840762 Phase 4
2 Impact of Starting a Dolutegravir-based Regimen on HIV-1 Proviral DNA Reservoir Of Treatment Naïve and Experienced Patients Unknown status NCT02370979 Phase 4
3 Effect of Maraviroc (MCV) on the Immunological Recovery of HIV-1 Discordant Patients With CD4 Lymphocyte Counts Below 200 Cells/mm3 Unknown status NCT01235013 Phase 4 Maraviroc
4 Maraviroc (Celsentri) With Raltegravir and Darunavir/Ritonavir for the Treatment of Triple Class Failure in Adult HIV-1 Infected Patients Unknown status NCT01013987 Phase 4 maraviroc;Raltegravir;Darunavir/ritonavir
5 Efficacy and Safety of Raltegravir (RAL) in Treatment-experienced HIV-1 Infected Adult Chinese Patients Unknown status NCT01201239 Phase 4 raltegravir
6 Effects of Mycophenolate Mofetil (MMF) on Surrogate Markers for Cardiovascular Disease in HIV-1 Infected Patients Unknown status NCT00247494 Phase 4 mycophenol mofetil (MMF, Cellcept®) 500 mg BID
7 Safety and Immune Response to Adjuvanted A(H1N1)v Influenza Vaccine in HIV-1 Infected and Immunosuppressed Adult Patients Unknown status NCT01017172 Phase 4
8 A Pilot Study of Triple NtRTI/NsRTI Therapy in Antiretroviral Naive HIV-1 Infected Patients Unknown status NCT00199121 Phase 4 Zidovudine (drug)
9 Mycophenolate Mofetil in Antiretroviral Naïve Patients 2 (MAN2 Study) Unknown status NCT00120419 Phase 4 mycophenol mofetil (MMF, Cellcept®) 500 mg BID
10 PI Vs. NNRTI Based Therapy for HIV Advanced Disease Unknown status NCT00162643 Phase 4 zidovudine+lamivudine+lopinavir/ritonavir;zidovudine + lamivudine + efavirenz
11 Alendronate for Prevention of AntiRetroviral Therapy-associated Bone Loss Unknown status NCT02322099 Phase 4 Alendronate;Placebo;Tenofovir disoproxil
12 RAL+ATV/r in Comparison With TDF/FTC (or 3TC) +ATV/r in HIV Infected Patients Unknown status NCT01829802 Phase 4 Ritonavir boosted Atazanavir;Raltegravir;TDF/FTC (or 3TC)
13 Open Label, Pilot Study of Darunavir Boosted by Cobicistat in Combination With Rilpivirine to Treat HIV+ Naïve Subjects Unknown status NCT02404233 Phase 4 darunavir/cobicistat;rilpivirine
14 Treatment With Nelfinavir or Efavirenz of HIV-Infected Patients Who Have Never Received Anti-HIV Drugs Unknown status NCT00005000 Phase 4 Nelfinavir mesylate;Efavirenz;Lamivudine;Keyhole-Limpet Hemocyanin;Stavudine;Zidovudine;Didanosine
15 Effectiveness and Safety of Epivir/Ziagen/Zerit (3TC/ABC/d4T) Versus Epivir/Ziagen/Sustiva (3TC/ABC/EFV) Versus Epivir/Ziagen/Agenerase/Norvir (3TC/ABC/APV/RTV) in HIV Patients Who Have Never Received Treatment Unknown status NCT00005017 Phase 4 Ritonavir;Abacavir sulfate;Amprenavir;Efavirenz;Lamivudine;Stavudine
16 Safety and Effectiveness of TRIZIVIR (Abacavir/Lamivudine/Zidovudine) With Efavirenz in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs Unknown status NCT00011895 Phase 4 Abacavir sulfate, Lamivudine and Zidovudine;Efavirenz
17 Protease Inhibitor Monotherapy Versus Ongoing Triple-therapy in the Long Term Management of HIV Infection (PIVOT) Unknown status NCT01230580 Phase 4 Protease Inhibitor;Standard-of-care Antiretroviral therapy
18 SHARE: Simple HAART With Abacavir, Reyataz, and Epivir Unknown status NCT00426296 Phase 4 atazanavir (Reyataz);ritonavir (Norvir)
19 Raltegravir + Lamivudine/Abacavir in HIV/Tuberculosis Co-Infected Patients Unknown status NCT01059422 Phase 4 Raltegravir; Abacavir/Lamivudine
20 MEDICLAS Study (Metabolic Effects of Different Classes of AntiretroviralS) Unknown status NCT00122226 Phase 4 Lopinavir/ritonavir + zidovudine + lamivudine;Lopinavir/ritonavir + nevirapine
21 Efavirenz to Dolutegravir Switch in Patients With CNS Toxicity Unknown status NCT02285374 Phase 4 Dolutegravir, efavirenz, efavirenz/emtricitabine/tenofovir
22 Maraviroc Abacavir STudy - Effect on Endothelial Recovery Unknown status NCT01389063 Phase 4 Maraviroc
23 Efficacy of PTX+IFN Alpha+ RBV on Hepatitis C Virus Coinfected HIV Patients Unknown status NCT02008214 Phase 4 Pentoxifylline;Placebo
24 Simplification From Protease Inhibitors to Raltegravir Unknown status NCT00941083 Phase 4 Raltegravir (Use RAL as a simplification strategy);Raltegravir (Use RAL as a simplification strategy);Raltegravir (Use RAL as a simplification strategy)
25 Safety and Efficacy Study Comparing Raltegravir to a Protease Inhibitor in Treatment-naïve, HIV/Hepatitis C Drug Users Unknown status NCT01105611 Phase 4 Raltegravir;Atazanavir/Ritonavir
26 Botswana Combination Prevention Project Unknown status NCT01965470 Phase 4
27 Once Daily 3TC, Efavirenz and ddI for HIV Infection Unknown status NCT00214435 Phase 4 once daily minimum 3-drug regimen of anti-retroviral medications
28 Darunavir/Ritonavir + Lamivudine Versus Darunavir/Ritonavir +Emtricitabine/Tenofovir in Naïve HIV-1 Infected Subjects Completed NCT02770508 Phase 4 darunavir/ritonavir;Lamivudine;emtricitabine-tenofovir(FTC/TDF)
29 The Partners Scale-Up Project Recruiting NCT03052010 Phase 4 PrEP;ART
30 Evaluation of the Efficacy and Safety Between Two Antiretroviral Regimens, in HIV-1-infected Treatment-naïve Subjects With Low CD4 Counts Completed NCT01928407 Phase 4 DARUNAVIR;ATAZANAVIR
31 Efficacy and Safety of a Simplification Treatment Based on Dolutegravir and Darunavir / Cobicistat vs Usual Treatment in Suppressed HIV-1-infected Patients With Multidrug Resistance. Recruiting NCT03683524 Phase 4 Dolutegravir (DTG) plus Darunavir/cobicistat (DRV/cobi).;Current ART
32 Evolution of Plasma Lipid Profile in Patients With HIV1 Who Change Atripla to Eviplera Compared to Continue With Atripla Completed NCT02547844 Phase 4 efavirenz + emtricitabina + tenofovir;rilpivirina + emtricitabina + tenofovir
33 Early Access to Low-dose Ritonavir (TMC114/r) and Other Antiretrovirals (ARVs) for Treatment-naive or Early Treatment Experienced in HIV-1 Patients Completed NCT01702090 Phase 4 TMC114/ritonavir
34 Valacyclovir vs. Acyclovir as HSV-2 Suppressive Therapy: Effect on Plasma HIV-1 Levels Among HIV-1/HSV-2 Co-infected Persons Completed NCT01026454 Phase 4 acyclovir;valacyclovir
35 A Study of Fuzeon (Enfuvirtide) With an Integrase Inhibitor Plus Optimized Background in Treatment-Experienced HIV-1 Infected Patients Terminated NCT00488059 Phase 4 enfuvirtide [Fuzeon];Optimized background ARV;Integrase inhibitor;enfuvirtide [Fuzeon]
36 BLQ Study: A Study of a Protease Inhibitor With Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With HIV-1. Completed NCT00326963 Phase 4 Background ARVs;PI;enfuvirtide [Fuzeon]
37 Atazanavir/Ritonavir, Once Daily + Raltegravir, Twice Daily, Switch Study in HIV-1—Infected Patients Completed NCT01332227 Phase 4 Atazanavir;Ritonavir (heat-stable);Raltegravir;Tenofovir/Emtricitabine
38 Peripheral Body Fat Distribution After Switching Zidovudine and Lamivudine to Truvada Completed NCT00324649 Phase 4 Truvada;Zidovudine/lamivudine
39 Raltegravir (Isentress/MK-0518) and HIV-1 Infected CD4 Cells During Acute/Early HIV-1 Terminated NCT00781287 Phase 4 3-drug anti-HIV therapy;Raltegravir
40 Compare the Efficacy and Safety of Raltegravir Versus Efavirenz Combination Therapy in Treatment-naïve HIV-1 Patients Completed NCT01989910 Phase 4 Raltegravir;Efavirenz
41 Safety and Efficacy Study of Switching From Epzicom to Truvada Completed NCT00724711 Phase 4 emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF);abacavir (ABC)/lamivudine (3TC)
42 HIV-1 Viral Dynamics in Subjects Initiating Raltegravir Therapy in Spain Completed NCT00685191 Phase 4 Salvage antiretroviral therapy including raltegravir
43 Tenofovir DF (Disoproxil Fumarate) in Combination With Emtricitabine in HIV-1 Patients Completed NCT00106379 Phase 4 Truvada (tenofovir DF + emtricitabine);Emtriva (emtricitabine);Viread (tenofovir DF)
44 Clinical Trial to Evaluate the Efficacy, Pharmacokinetics (PK) Interactions and Safety of Dolutegravir Plus 2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in HIV‐1‐Infected Solid Organ Transplant Patients Recruiting NCT03360682 Phase 4 Lamivudine 300 MG;Abacavir 600 MG;Dolutegravir 50 mg;Tenofovir Disoproxil 245Mg Tablet;Emtricitabine 200 MG
45 A Simplification Study of Unboosted Reyataz With Epzicom (ASSURE) Completed NCT01102972 Phase 4 Reyataz + Norvir + Truvada;Reyataz + Epzicom
46 B/F/TAF vs Atripla Double-Blind Switch Study in HIV-1 Infected Adults Recruiting NCT03532425 Phase 4 B/F/TAF;Atripla;B/F/TAF Placebo;Atripla Placebo
47 Efficacy, Safety & Tolerability of Switching EFV/TDF/FTC to BIC/FTC/TAF in Virologically Suppressed Adults With HIV-1 Recruiting NCT03502005 Phase 4 bictegravir/emtricitabine/tenofovir alafenamide
48 Sequential HIV Therapy in Treatment Resistant HIV-1 Infected Patients Terminated NCT00128908 Phase 4 Standard Continuous Highly Active Antiretroviral Therapy (HAART);Rapidly Cycled HAART
49 Study to Compare the Virologic Efficacy in Cerebrospinal Fluid (CSF) and Neurocognitive State in Patients Infected by HIV-1 Long-term Treatment (> 3 Years) With Lopinavir / Ritonavir Monotherapy Completed NCT01116817 Phase 4
50 Impact of HIV-1 and Aging on Mucosal Vaccine Responses Recruiting NCT03729778 Phase 4

Search NIH Clinical Center for Human Immunodeficiency Virus Type 1

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Human Immunodeficiency Virus Type 1 cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Human Immunodeficiency Virus Type 1:
AGS-004, electroporated mature dendritic cells for HIV
Embryonic/Adult Cultured Cells Related to Human Immunodeficiency Virus Type 1:
Maturated and electroporated dendritic cells PMIDs: 20636001

Genetic Tests for Human Immunodeficiency Virus Type 1

Genetic tests related to Human Immunodeficiency Virus Type 1:

# Genetic test Affiliating Genes
1 Human Immunodeficiency Virus Type 1, Susceptibility to 29 CCL11 CCL2 CCL3 CCL3L1 CD209 CX3CR1 CXCL12 CXCR1 HLA-C IFNG IL10 IL4R KIR3DL1 TLR3

Anatomical Context for Human Immunodeficiency Virus Type 1

MalaCards organs/tissues related to Human Immunodeficiency Virus Type 1:

41
Testes, T Cells, Brain, Monocytes, Bone, Liver, Lung

Publications for Human Immunodeficiency Virus Type 1

Articles related to Human Immunodeficiency Virus Type 1:

(show top 50) (show all 4072)
# Title Authors Year
1
Risk analysis and seroprevalence of HEV in people living with HIV/AIDS in Brazil. ( 30292751 )
2019
2
Towards achieving the fast-track targets and ending the epidemic of HIV/AIDS in Ethiopia: Successes and challenges. ( 30391417 )
2019
3
Molecular Biology of KSHV in Relation to HIV/AIDS-Associated Oncogenesis. ( 30523620 )
2019
4
Molecular Biology of EBV in Relationship to HIV/AIDS-Associated Oncogenesis. ( 30523622 )
2019
5
HPV-Associated Oropharyngeal Cancer in the HIV/AIDS Patient. ( 30523624 )
2019
6
HPV-Associated Anal Cancer in the HIV/AIDS Patient. ( 30523625 )
2019
7
Human immunodeficiency virus type 1 (HIV-1)-mediated neuroinflammation dysregulates neurogranin and induces synaptodendritic injury. ( 29703241 )
2018
8
Immunogenetic factors in early immune control of human immunodeficiency virus type 1 (HIV-1) infection: Evaluation of HLA class I amino acid variants in two African populations. ( 29289742 )
2018
9
Molecular identification of tick-borne pathogens in asymptomatic individuals with human immunodeficiency virus type 1 (HIV-1) infection: a retrospective study. ( 29776392 )
2018
10
Phylogenetic and temporal dynamics of human immunodeficiency virus type 1 CRF01_AE and CRF07_BC among recently infected antiretroviral therapy-naA^ve men who have sex with men in Jiangsu province, China, 2012 to 2015: A molecular epidemiology-based study. ( 29419684 )
2018
11
Human Immunodeficiency Virus Type-1 Elite Controllers Maintain Low Co-Expression of Inhibitory Receptors on CD4+ T Cells. ( 29403500 )
2018
12
Immunogenicity of NYVAC Prime-Protein Boost Human Immunodeficiency Virus Type 1 Envelope Vaccination and Simian-Human Immunodeficiency Virus Challenge of Nonhuman Primates. ( 29437967 )
2018
13
Expression of Human Immunodeficiency Virus type 1 (HIV-1) coat protein genes in plants using cotton leaf curl Multan betasatellite-based vector. ( 29304063 )
2018
14
In vitro basal T-cell proliferation among asymptomatic Human T cell Leukemia Virus type 1 patients co-infected with hepatitis C and/or Human Immunodeficiency Virus type 1. ( 29499169 )
2018
15
Inclusion body myositis and human immunodeficiency virus type 1: A new case report and literature review. ( 29426734 )
2018
16
Context-dependent autoprocessing of human immunodeficiency virus type 1 protease precursors. ( 29338056 )
2018
17
Experimental Adaptive Evolution of Simian Immunodeficiency Virus SIVcpz to Pandemic Human Immunodeficiency Virus Type 1 by Using a Humanized Mouse Model. ( 29212937 )
2018
18
Nonreactive Human Immunodeficiency Virus Type 1 Rapid Tests After Sustained Viral Suppression Following Antiretroviral Therapy Initiation During Primary Infection. ( 29509924 )
2018
19
Development of a Live Recombinant BCG Expressing Human Immunodeficiency Virus Type 1 (HIV-1) Gag Using a pMyong2 Vector System: Potential Use As a Novel HIV-1 Vaccine. ( 29636755 )
2018
20
Genotypic Characterization of Human Immunodeficiency Virus Type 1 Prevalent in Kepulauan Riau, Indonesia. ( 29589465 )
2018
21
Analysis of Select Herpes Simplex Virus 1 (HSV-1) Proteins for Restriction of Human Immunodeficiency Virus Type 1 (HIV-1): HSV-1 gM Protein Potently Restricts HIV-1 by Preventing Intracellular Transport and Processing of Env gp160. ( 29093081 )
2018
22
Identification of a Conserved Interface of Human Immunodeficiency Virus Type 1 and Feline Immunodeficiency Virus Vifs with Cullin 5. ( 29263270 )
2018
23
Acquisition of Multidrug-Resistant Human Immunodeficiency Virus Type 1 Infection in a Patient Taking Preexposure Prophylaxis. ( 29961859 )
2018
24
Discovery of the Human Immunodeficiency Virus Type 1 (HIV-1) Attachment Inhibitor Temsavir and its Phosphonooxymethyl Prodrug Fostemsavir. ( 29920093 )
2018
25
Human Immune System Mice for the Study of Human Immunodeficiency Virus-Type 1 Infection of the Central Nervous System. ( 29670623 )
2018
26
Indolylarylsulfones, a fascinating story of highly potent human immunodeficiency virus type 1 non-nucleoside reverse transcriptase inhibitors. ( 29417826 )
2018
27
Trametinib suppresses HIV-1 replication by interfering with the disassembly of human immunodeficiency virus type 1 capsid core. ( 29197575 )
2018
28
Quercetin synergistically reactivates human immunodeficiency virus type 1 latency by activating nuclear factora89I_B. ( 29207194 )
2018
29
O-GalNAcylation of RANTES Improves Its Properties as a Human Immunodeficiency Virus Type 1 Entry Inhibitor. ( 29202246 )
2018
30
Induction of a Na<sup>+</sup>/K<sup>+</sup>-ATPase-Dependent Form of Autophagy Triggers Preferential Cell Death of Human Immunodeficiency Virus Type-1-Infected Macrophages. ( 29962265 )
2018
31
Formation of RNA Granule-Derived Capsid Assembly Intermediates Appears To Be Conserved between Human Immunodeficiency Virus Type 1 and the Nonprimate Lentivirus Feline Immunodeficiency Virus. ( 29467316 )
2018
32
Virion-Packaged Pyruvate Kinase Muscle Type 2 Affects Reverse Transcription Efficiency of Human Immunodeficiency Virus Type 1 by Blocking Virion Recruitment of tRNA<sup>Lys3</sup>. ( 29607934 )
2018
33
Detection of IgG3 antibodies specific to the human immunodeficiency virus type 1 (HIV-1) p24 protein as marker for recently acquired infection. ( 29925445 )
2018
34
Identification of Highly Potent Human Immunodeficiency Virus Type-1 Protease Inhibitors against Lopinavir and Darunavir Resistant Viruses from Allophenylnorstatine-Based Peptidomimetics with P2 Tetrahydrofuranylglycine. ( 29852069 )
2018
35
Adherence and virologic outcomes among treatment-naA^ve veteran patients with human immunodeficiency virus type 1 infection. ( 29480831 )
2018
36
Inhibition of Human Immunodeficiency Virus Type 1 Entry by a Keggin Polyoxometalate. ( 29772712 )
2018
37
Six-helix bundle completion in the distal C-terminal heptad repeat region of gp41 is required for efficient human immunodeficiency virus type 1 infection. ( 29609648 )
2018
38
Iranian HIV/AIDS patients with oropharyngeal candidiasis: identification, prevalence and antifungal susceptibility of Candida species. ( 30019443 )
2018
39
Moyamoya syndrome in a pediatric patient with congenital human immunodeficiency virus type 1 infection resulting in intracranial hemorrhage. ( 29138020 )
2018
40
Socio-Behavioral Risk Factors Associated with Cryptosporidiosis in HIV/AIDS Patients Visiting the HIV Referral Clinic at Cape Coast Teaching Hospital, Ghana. ( 30369995 )
2018
41
Gender disparities in depression severity and coping among people living with HIV/AIDS in Kolkata, India. ( 30462688 )
2018
42
Structural equation modeling analysis of social support, coping strategies, depression and suicidal ideation among people living with HIV/AIDS in Changsha, China. ( 30464476 )
2018
43
Prevalence and associated factors of depression among patients with HIV/AIDS in Hawassa, Ethiopia, cross-sectional study. ( 30386408 )
2018
44
Posterior reversible encephalopathy syndrome in a patient with HIV/AIDS and immune reconstitution syndrome: a case study and literature review. ( 30151215 )
2018
45
A cross-sectional comparative study of perceived stigma between patients with epilepsy and patients living with HIV/AIDS in Accra, Ghana. ( 30384093 )
2018
46
Prevalence of extrapulmonary tuberculosis among people living with HIV/AIDS in sub-Saharan Africa: a systemic review and meta-analysis. ( 30464643 )
2018
47
National estimates of case-mix, mortality, and economic outcomes among inpatient HIV/AIDS mono-infection and hepatitis C co-infection cases in the US. ( 30485617 )
2018
48
Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Coinfected With Hepatitis C Virus and Human Immunodeficiency Virus Type 1: The EXPEDITION-2 Study. ( 29566246 )
2018
49
Multicenter Validation of Commercial Antigenuria Reagents To Diagnose Progressive Disseminated Histoplasmosis in People Living with HIV/AIDS in Two Latin American Countries. ( 29563205 )
2018
50
Simultaneous Knockout of CXCR4 and CCR5 Genes in CD4+ T Cells via CRISPR/Cas9 Confers Resistance to Both X4- and R5-Tropic Human Immunodeficiency Virus Type 1 Infection. ( 28599597 )
2018

Variations for Human Immunodeficiency Virus Type 1

ClinVar genetic disease variations for Human Immunodeficiency Virus Type 1:

6 (show all 22)
# Gene Variation Type Significance SNP ID Assembly Location
1 CD209 CD209, -336A-G single nucleotide variant protective,risk factor
2 CCR5 NM_000579.3(CCR5): c.554_585del32 (p.Ser185Ilefs) deletion protective,risk factor rs333 GRCh37 Chromosome 3, 46414947: 46414978
3 CCR5 NM_000579.3(CCR5): c.554_585del32 (p.Ser185Ilefs) deletion protective,risk factor rs333 GRCh38 Chromosome 3, 46373456: 46373487
4 CCR5 NM_000579.3(CCR5): c.303T> A (p.Cys101Ter) single nucleotide variant protective rs1800560 GRCh37 Chromosome 3, 46414696: 46414696
5 CCR5 NM_000579.3(CCR5): c.303T> A (p.Cys101Ter) single nucleotide variant protective rs1800560 GRCh38 Chromosome 3, 46373205: 46373205
6 CCR5 NM_000579.3(CCR5): c.-301+246A> G single nucleotide variant protective rs1799987 GRCh37 Chromosome 3, 46411935: 46411935
7 CCR5 NM_000579.3(CCR5): c.-301+246A> G single nucleotide variant protective rs1799987 GRCh38 Chromosome 3, 46370444: 46370444
8 CCR5 NM_000579.3(CCR5): c.180G> T (p.Arg60Ser) single nucleotide variant protective rs1800940 GRCh37 Chromosome 3, 46414573: 46414573
9 CCR5 NM_000579.3(CCR5): c.180G> T (p.Arg60Ser) single nucleotide variant protective rs1800940 GRCh38 Chromosome 3, 46373082: 46373082
10 CCR2 NM_001123041.2(CCR2): c.190G> A (p.Val64Ile) single nucleotide variant protective rs1799864 GRCh37 Chromosome 3, 46399208: 46399208
11 CCR2 NM_001123041.2(CCR2): c.190G> A (p.Val64Ile) single nucleotide variant protective rs1799864 GRCh38 Chromosome 3, 46357717: 46357717
12 CCL11 CCL11, -1385G-A single nucleotide variant protective
13 CXCL12 NM_000609.6(CXCL12): c.266+535G> A single nucleotide variant protective rs387906400 GRCh37 Chromosome 10, 44873550: 44873550
14 CXCL12 NM_000609.6(CXCL12): c.266+535G> A single nucleotide variant protective rs387906400 GRCh38 Chromosome 10, 44378102: 44378102
15 CCL2 CCL2, 767C-G single nucleotide variant protective
16 CCL2 CCL2, -2136A-T single nucleotide variant protective
17 HLA-C NC_000006.12: g.31306603T> C single nucleotide variant risk factor rs9264942 GRCh38 Chromosome 6, 31306603: 31306603
18 HLA-C NC_000006.12: g.31306603T> C single nucleotide variant risk factor rs9264942 GRCh37 Chromosome 6, 31274380: 31274380
19 IL10 NM_000572.2(IL10): c.-627A> C single nucleotide variant protective,risk factor rs1800872 GRCh38 Chromosome 1, 206773062: 206773062
20 IL10 NM_000572.2(IL10): c.-627A> C single nucleotide variant protective,risk factor rs1800872 GRCh37 Chromosome 1, 206946407: 206946407
21 TLR3 NM_003265.2(TLR3): c.1234C> T (p.Leu412Phe) single nucleotide variant protective rs3775291 GRCh37 Chromosome 4, 187004074: 187004074
22 TLR3 NM_003265.2(TLR3): c.1234C> T (p.Leu412Phe) single nucleotide variant protective rs3775291 GRCh38 Chromosome 4, 186082920: 186082920

Copy number variations for Human Immunodeficiency Virus Type 1 from CNVD:

7 (show all 23)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13736 1 1 247249719 Copy number HIV/AIDS
2 74031 13 1 114142980 Copy number HIV/AIDS
3 107129 17 1225928 31649829 Copy number CCL3L3 HIV/AIDS
4 107135 17 1225928 31649843 Copy number CCL3L1 HIV/AIDS
5 107136 17 1225928 31649843 Copy number CCL3L1 HIV/AIDS
6 107137 17 1225928 31649843 Copy number CCL3L1 HIV/AIDS
7 107145 17 1225928 31649843 Segmental duplicatio ns CCL3L1 HIV/AIDS
8 107159 17 1242109 31665953 Copy number CCL4L2 HIV/AIDS
9 110228 17 31562580 31665959 Copy number CCL4L1 HIV/AIDS
10 110279 17 31800000 38100000 Copy number CCL3L1 HIV/AIDS
11 110285 17 31800000 38100000 Copy number CCL4L1 HIV/AIDS
12 110286 17 31800000 38100000 Copy number CCL4L1 HIV/AIDS
13 110848 17 34522267 34625730 Copy number CCL3L1 HIV/AIDS
14 111275 17 35400000 35600000 Copy number CCL3L1 HIV/AIDS
15 112166 17 38100000 38400000 Copy number CCL3L1 HIV/AIDS
16 112167 17 38100000 38400000 Copy number CCL3L1 HIV/AIDS
17 112170 17 38100000 38400000 Loss CCL3L1 HIV/AIDS
18 179925 4 1 191273063 Copy number HIV/AIDS
19 209403 6 2614953 31491069 Copy number MICA HIV/AIDS
20 211349 6 32593131 32665540 Copy number HLA-DRB5 HIV/AIDS
21 212276 6 3674895 32665540 Copy number HLA-DRB1 HIV/AIDS
22 212425 6 3795995 32719407 Copy number HLA-DQA1 HIV/AIDS
23 212441 6 3813334 32742444 Copy number HLA-DQB1 HIV/AIDS

Expression for Human Immunodeficiency Virus Type 1

Search GEO for disease gene expression data for Human Immunodeficiency Virus Type 1.

Pathways for Human Immunodeficiency Virus Type 1

Pathways related to Human Immunodeficiency Virus Type 1 according to GeneCards Suite gene sharing:

(show all 37)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.99 CCL11 CCL2 CCL3 CCL3L1 CCR2 CCR5
2
Show member pathways
13.83 CCL11 CCL2 CCL3 CCL3L1 CCR2 CCR5
3
Show member pathways
13.63 CCL11 CCL2 CCL3 CCL3L1 CCR2 CCR5
4
Show member pathways
13.5 CCL11 CCL2 CCL3 CCL3L1 CXCL12 IFNG
5
Show member pathways
13.37 CCL11 CCL2 CCL3 CCL3L1 CCR2 CCR5
6
Show member pathways
13.33 CCL11 CCL2 CCL3 CCL3L1 CCR2 CCR5
7
Show member pathways
13.17 CCL11 CCL2 CCL3 CCL3L1 CCR2 CCR5
8
Show member pathways
13.08 CCL11 CCL2 CCL3 CCL3L1 CCR2 CCR5
9
Show member pathways
13.03 CCL2 CCL3 CCL3L1 CCR5 CXCL12 HLA-C
10
Show member pathways
12.98 CCL2 CCL3 CCL3L1 IFNG IL10 TLR3
11
Show member pathways
12.87 CCL11 CXCL12 HLA-C IFNG IL10 IL4R
12
Show member pathways
12.74 CCL2 CD209 HLA-C IFNG TLR3
13
Show member pathways